Appleby Advises on LumiraDx NASDAQ Listing
Appleby has acted as Cayman counsel to LumiraDX Limited (LumiraDx) in connection with its listing on Nasdaq. LumiraDx, a next-generation point of care diagnostics company, effected the listing through a reverse triangular merger with CA Healthcare Acquisition Corp (CAHC), a blank-check special acquisition company. Trading on Nasdaq began on 29 September 2021 under the ticker symbol “LMDX” for the common shares and “LMDXW” for the warrants assumed by LumiraDx from CAHC.
LumiraDx currently has 5 LumiraDx Platform tests in the market, including its comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions. The LumiraDx platform is being used by CVS Pharmacy Inc in the U.S., the National Health Service and Boots in the UK, a significant number of accident and emergency rooms in Italy and other parts of Europe, hospital systems in Japan and across South America, and is being deployed in partnership with the Bill & Melinda Gates Foundation in a growing number of African countries where access to high quality diagnostics is limited.
The Appleby team was led by Andrew Weaver, a partner based in the firm’s Jersey office, Simon Raftopoulos, and Anna-Lise Wisdom, both partners based in the firm’s Cayman Islands office, with support from Chris Smedley, an associate in the firm’s Jersey office, and Appolina Bent, an associate, in the firm’s Cayman Islands office.
Andrew Weaver commented, “This is a significant milestone for LumiraDx. It has been a pleasure working alongside Fried Frank, Harris, Shriver & Jacobson LLP and Goodwin Procter LLP on this deal and we have no doubt that LumiraDx will be highly successful in accelerating its expansion.”
